Abstract
This article gives an overview about the development of human therapeutic antibodies generated by phage display. After an introduction to the method, the focus is on approved antibodies and those currently in clinical trials, 14 of which are described in detail.
Keywords: Therapeutic Antibodies, phage display, clinical trials, CHO producer cells, immune system, GENE LIBRARIES
Current Pharmaceutical Biotechnology
Title: Phage Display Derived Therapeutic Antibodies
Volume: 9 Issue: 6
Author(s): Holger Thie, Torsten Meyer, Thomas Schirrmann, Michael Hust and Stefan Dubel
Affiliation:
Keywords: Therapeutic Antibodies, phage display, clinical trials, CHO producer cells, immune system, GENE LIBRARIES
Abstract: This article gives an overview about the development of human therapeutic antibodies generated by phage display. After an introduction to the method, the focus is on approved antibodies and those currently in clinical trials, 14 of which are described in detail.
Export Options
About this article
Cite this article as:
Thie Holger, Meyer Torsten, Schirrmann Thomas, Hust Michael and Dubel Stefan, Phage Display Derived Therapeutic Antibodies, Current Pharmaceutical Biotechnology 2008; 9 (6) . https://dx.doi.org/10.2174/138920108786786349
DOI https://dx.doi.org/10.2174/138920108786786349 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Natural Coumarins as a Novel Class of Neuroprotective Agents
Mini-Reviews in Medicinal Chemistry Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology Decoding the Inter-Relationship between Sleep Disorders and Alzheimer’s Disease Pathogenesis
CNS & Neurological Disorders - Drug Targets Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Current Trends in the Use of Cationic Polymer Assemblies for siRNA and Plasmid DNA Delivery
Pharmaceutical Nanotechnology Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Tumor Specific Novel Taxoid-Monoclonal Antibody Conjugates
Current Medicinal Chemistry Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Conformation as the Therapeutic Target for Neurodegenerative Diseases
Current Alzheimer Research Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets